Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study
Restricted accessResearch articleFirst published online August, 2012
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study
Aims: In an international prospective cohort study we assessed the relationship between glucose levels and incident cardiovascular events and death.
Methods and results: 18,990 men and women were screened for entry into the DREAM clinical trial from 21 different countries. All had clinical and biochemical information collected at baseline, including an oral glucose tolerance test (OGTT), and were prospectively followed over a median (IQR) of 3.5 (3.0–4.0) years for incident cardiovascular (CV) events including coronary artery disease (CAD), stroke, congestive heart failure (CHF) requiring hospitalization, and death. After OGTT screening, 8000 subjects were classified as normoglycaemic, 8427 had impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), and 2563 subjects had newly diagnosed type 2 diabetes mellitus (DM). There were incident events in 491 individuals: 282 CAD, 54 strokes, 19 CHF, and 164 died. The annualized CV or death event rate was 0.79/100 person-years in the overall cohort, 0.51/100 person-years in normoglycaemics, 0.92/100 person-years among subjects with IFG and/or IGT at baseline, and 1.27/100 person-years among those with DM (p for trend <0.0001). Among all subjects, a 1 mmol/l increase in fasting plasma glucose (FPG) or a 2.52 mmol/l increase in the 2-h post-OGTT glucose was associated with a hazard ratio increase in the risk of CV events or death of 1.17 (95% CI 1.13–1.22).
Conclusions: In this large multiethnic cohort, the risk of CV events or death increased progressively among individuals who were normoglycaemic, IFG or IGT, and newly diagnosed diabetics. A 1 mmol/l increase in FPG was associated with a 17% increase in the risk of future CV events or death. Therapeutic or behavioural interventions designed to either prevent glucose levels from rising, or lower glucose among individuals with dysglycaemia should be evaluated.
International Diabetes Federation. Diabetes atlas,2nd ed. Brussels: International Diabetes Federation, 2003. http://www.eatlas.idf.org/ (2009, consulted February 2009).
2.
CoutinhoMGersteinHCWangYYusufS. The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care1999; 22(2): 233–240.
3.
Emerging Risk Factors CollaborationSarwarNGaoPSeshasaiSRGobinRKaptogeS. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet2010; 375(9733): 2215–2222.
4.
GersteinHC. Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evid Based Cardiovasc Med1997; 1(4): 87–88.
5.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010; 33(Suppl 1): S62–S69.
6.
FordESZhaoGLiC. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol2010; 55(13): 1310–1317.
7.
EyreHKahnRRoberstonRMClarkNGDoyleCHongY. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation2004; 109(25): 3244–3255.
8.
GersteinHCYusufSHolmanRBoschJPogueJ. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia2004; 47(9): 1519–1527.
9.
DREAM Trial InvestigatorsBoschJYusufSGersteinHCPogueJSheridanP. Effect of ramipril on the incidence of diabetes. N Engl J Med2006; 355(15): 1551–1562.
10.
GenuthSAlbertiKGBennettPBuseJDefronzoRKahnR. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care2003; 26(11): 3160–3167.
11.
GreenlandS. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology1995; 6(4): 356–365.
12.
ChiassonJLJosseRGGomisRHanefeldMKarasikALaaksoM. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002 Jun 15; 359(9323): 2072–2077.
13.
KnowlerWCBarrett-ConnorEFowlerSEHammanRFLachinJMWalkerEA. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346(6): 393–403.
14.
ORIGIN Trial InvestigatorsGersteinHYusufSRiddleMCRydenLBoschJ. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J2008; 155(1): 26–32.
15.
CaliffRMBoolellMHaffnerSMBethelMAMcMurrayJDuggalA. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J2008; 156(4): 623–632.
16.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsGersteinHCYusufSBoschJPogueJSheridanP. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet2006; 368(9541): 1096–1105.
17.
LaaksoM. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med1996; 124(1 Pt 2): 127–130.
18.
WeiMGaskillSPHaffnerSMSternMP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care1998; 21(7): 1167–1172.
19.
de VegtFDekkerJMJagerAHienkensEKostensePJStehouwerCD. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA2001; 285(16): 2109–2113.
20.
UnwinNShawJZimmetPAlbertiKG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med2002; 19(9): 708–723.
21.
RasmussenSSGlümerCSandbaekALauritzenTBorch-JohnsenK. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. Diabetologia2008; 51(2): 249–257.
22.
Abdul-GhaniMAWilliamsKDeFronzoRSternM. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care2006; 29(7): 1613–1618.
23.
FerranniniEMassariMNannipieriMNataliARidauraRLGonzales-VillalpandoC. Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. Diabetologia2009; 52(5): 818–824.
24.
McNeelyMJBoykoEJLeonettiDLKahnSEFujimotoWY. Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care2003; 26(3): 758–763.
25.
WangJJYuanSYZhuLXFuHJLiHBHuG. Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose. Diabetes Res Clin Pract2004; 66(2): 183–191.
26.
CheungBMWatNMManYBTamSThomasGNLeungGM. Development of diabetes in Chinese with the metabolic syndrome: a 6-year prospective study. Diabetes Care2007; 30(6): 1430–1436.
27.
de VegtFDekkerJMRuhéHGStehouwerCDNijpelsGBouterLM. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia1999; 42(8): 926–931.
28.
BalkauBHuGQiaoQTuomilehtoJBorch-JohnsenKPyöräläK. DECODE Study Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia2004; 47(12): 2118–2128.
29.
SaydahSHMiretMSungJVarasCGauseDBrancatiFL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care2001; 24(8): 1397–1402.
30.
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med2001; 161(3): 397–405.
31.
MeigsJBNathanDMD'AgostinoRBSrWilsonPW. Framingham Offspring Study. Fasting and post-challenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care2002; 25(10): 1845–1850.
32.
TominagaMEguchiHManakaHIgarashiKKatoTSekikawaA. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care1999; 22(6): 920–924.
33.
TaiESGohSYLeeJJWongMSHengDHughesK. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care2004; 27(7): 1728–1734.
34.
ConenDRidkerPMMoraSBuringJEGlynnRJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J2007; 28(23): 2937–2943.
35.
HeidemannCSunQvan DamRMMeigsJBZhangCTworogerSS. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med2008; 149(5): 307–316.
